CASI Pharmaceuticals Appoints James Huang to Board of Directors
凯信远达(US:CASI) Accessnewswire·2025-09-26 21:45- Industry veteran brings over 35 years of biotech experience as a successful entrepreneur and investor - Operating experience to significantly enhance development program of CID-103 (anti-CD38 mAb) SOUTH SAN FRANCISCO, CA / ACCESS Newswire / September 26, 2025 / CASI Pharmaceuticals, Inc. (NASDAQ:CASI), a clinical-stage biopharmaceutical company focused on developing innovative therapies for patients with organ transplant rejection and autoimmune diseases, today announced the appointment of James Huang as ...